Predictive genetic testing for complex diseases: a public health perspective

C. Marzuillo, C. De Vito, E. D'Andrea, A. Rosso; P. Villari; QJM (2014) 107 (2): 93-97. doi: 10.1093/qjmed/hct190 First published online: September 17, 2013

17 / 09 / 2013

FEAM’s Spring Conference 2013

Future of Clinical Research: Karim Berkouk (EC) - Sir Michael Rawlins (UK) - Ebhlin Mulroe (IPPOSI) - Cyril Höschl (Czech Republic) - Juan Tamargo (Spain) - Sir Peter Lachmann (UK) - David Smith (Ireland) - Detlev Ganten (IAMP)

07 / 09 / 2013

Academic, hospital and charity sectors’ comments on amendments adopted by the European Parliament’s ENVI committee on the Clinical Trials Regulation

13 / 08 / 2013

Reforming the EU environment for clinical trials: what are the challenges?

R. Fears; H.E. Blum; D. Kelleher; F. Meunier; R. Souhami, QJM 2013; doi: 10.1093/qjmed/hct149

27 / 07 / 2013

A derogation for medical resonance imaging (MRI)

is approved by the European Parliament and the European Council on the revised EU Physical Agents Directive 2004/40/EC (press release)

25 / 07 / 2013

Comments from EASAC and FEAM on the In-vitro Diagnostic Medical Devices Regulation

25 / 05 / 2013

Proposal for an EU Regulation on Clinical Trials – A joint statement from non-commercial and commercial organisations

25 / 02 / 2013

Joint FEAM/Wellcome Trust proposed amendments

25 / 02 / 2013

Joint FEAM/Wellcome Trust briefing on data protection and proposed amendments

25 / 02 / 2013

Direct‐to‐Consumer Genetic Testing for Health‐Related Purposes in the European Union

Summary report from a meeting organised by EASAC, FEAM and STOA in the European Parliament on 3 December 2012

30 / 01 / 2013

Joint statement of the Healthcare Coalition on Data Protection

And press releasePress release

29 / 01 / 2013

Summary of the FEAM statement on the Data Protection Regulation and proposed amendments to the EC proposed Regulation

25 / 11 / 2012

The perspective of EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes

European Journal of Human Genetics,

21 / 11 / 2012

Summary of the report on Direct-to-consumer genetic testing for health-related purposes in the European Union: the view from EASAC and FEAM

25 / 08 / 2012

Direct-to-consumer genetic testing

The Lancet, Volume 380, Issue 9837, Page 76, 14 July 2012.

25 / 07 / 2012

Summary of FEAM Madrid conference on Ageing

4 May 2012, Spanish Royal National Academy of Medicine

30 / 06 / 2012

Direct-to-consumer genetic testing for health-related purposes in the European Union: the view from EASAC and FEAM

Report

30 / 06 / 2012

Summary of session on ageing

(FEAM Madrid Spring Conference 4-5 May 2012)

25 / 06 / 2012

FEAM statement on the data protection regulation

25 / 06 / 2012

Workshop on the Benefits of a Simplified and Coherent Clinical – Trials Framework in Europe

01 / 12 / 2011

FEAM statement on the EU Physical Agents Directive (2004/40/EC)

07 / 11 / 2011

Objectives and Opportunities for EU mental health policy

Account of the launch event of the FEAM statement on Mental Health Policy Issues (22 March 2011, European Parliament)

25 / 08 / 2011

Taking forward reform of the EU Clinical Trials Directive

Account of the launch event of the FEAM statement Opportunities and Challenges for Reforming the EU Clinical Trials Directive: an Academic Perspective (25 January 2011, European Parliament)

25 / 07 / 2011

European mental health policy: opportunities for science and innovation, challenges for implementation

(Robin Fears; Cyril Hoschl; The European Journal of Public Health 2011; doi: 10.1093/eurpub/ckr075). Free-access links to EJPH advance access page (October 2011 edition): Full Text: http://eurpub.oxfordjournals.org/cgi/content/full/ckr075? ijkey=Qt7fUZDrzfJIzbm&keytype=ref

25 / 07 / 2011

A response from FEAM to the European Commission consultation on the Green Paper ‘From Challenges to Opportunities

Towards a Common Strategic Framework for EU Research and Innovation funding'

25 / 05 / 2011